ABCs of natriuretic peptides: Cardiac aspects

Hormone Research

Volumn 67, Issue SUPPL. 1, 2007, Pages 77-80

  Nir, Amiram ^a,b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cardiac effects; Heart disease; Natriuretic peptides

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NESIRITIDE;

AMINO TERMINAL SEQUENCE; CARDIOPULMONARY HEMODYNAMICS; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONGENITAL HEART MALFORMATION; CONGESTIVE HEART FAILURE; DISEASE MARKER; HEART FAILURE; HEART LEFT RIGHT SHUNT; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE VOLUME; HEART RIGHT VENTRICLE VOLUME; HEART VENTRICLE PRESSURE; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THERAPY EFFECT; TREATMENT RESPONSE; VASCULAR RESISTANCE;

EID: 33847061181     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097557     Document Type: Conference Paper

References (30)

1. Mair J, Hammerer-Lercher A, Puschendorf B: The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-588.
2. Cowie MR, Mendez GF: BNP and congestive heart failure. Prog Cardiovasc Dis 2002;44:293-321.
3. Forero McGrath M, Kuroski de Bold ML, de Bold AJ: The endocrine function of the heart. Trends Endocrinol Metab 2005;16:469-477.
4. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A: Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004;102:223-241.
5. Kuhn M: Cardiac and intestinal natriuretic peptides: insights from genetically modified mice. Peptides 2005;26:1078-1085.
6. Publication Committee, for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-1540.
7. Sackner-Bernstein DJ, Kowalski M, Fox M, Aaronson K: Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905.
8. McCullough PA, Sandberg KR: Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003;4(suppl 4):S13-S19.
9. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, Gardetto N, Wanner E, Maisel AS: Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002;105:595-601.
10. Nakamura T, Sakamoto K, Yamano T, Kikkawa M, Zen K, Hikosaka T, Kubota T, Azuma A, Nishimura T: Increased plasma brain natriuretic peptide level as a guide for silent myocardial ischemia in patients with non-obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:1657-1663.
11. Kucher N, Printzen G, Goldhaber SZ: Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003;107:2545-2547.
12. Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, Zucchelli GC, Clerico A: Cardiac natriuretic hormones, neurohormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 2004;42:627-636.
13. Galasko GIW, Lahiri A, Barnes SC, Collinson P, Senior R: What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-2276.
14. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
15. Troughton RE, Farmpton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
16. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
17. Doust JA, Pietrzak E, Dobson A, Glasziou P: How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005;330:625-634.
18. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-654.
19. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr: Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-982.
20. Yoshibayashi M, Kamiya T, Saito Y, Nakao K, Nishioka K, Temma S, Itoh H, Shirakami G, Matsuo H: Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 1995;133:207-209.
21. Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJJT: N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in heart diseases. Acta Paediatr 2004;93:603-607.
22. Mir TS, Flato M, Falkenberg J, Haddad M, Budden R, Weil J, Albers S, Laer S: Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender. Pediatr Cardiol 2006;27:73-77.
23. Ohuchi H, Takasugi H, Ohashi H, Okada Y, Yamada O, Ono Y, Yagihara T, Echigo S: Stratification of pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activities in patients with congenital heart disease. Circulation 2003;108:2368-2376.
24. Westerlind A, Wahlander H, Lindstedt G, Lundberg PA, Holmgren D: Clinical signs of heart failure are associated with increased levels of natriuretic peptide types B and A in children with congenital heart defects or cardiomyopathy. Acta Paediatr 2004;93:340-345.
25. Cohen S, Springer C, Perles Z, Rein AJJT, Avital A, Argaman Z, Nir A: Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics 2005;115:1347-1350.
26. Suda K, Matsumura M, Matsumoto M: Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int 2003;45:249-254.
27. Gerber IL, Stewart RAH, Legget ME, West TM, French RL, Sutton TM, Yandle TG, French JK, Richards AM, White HD: Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-1890.
28. Reynolds EW, Ellington JG, Vranicar M, Bada HS: Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:1297-1304.
29. Claudius I, Lan YT, Chang RK, Wetzel GT, Alejos J: Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients. Am J Cardiol 2003;92:1368-1370.
30. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M: Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241-248.